NASDAQ:TRHC - Tabula Rasa HealthCare Stock Price, Forecast & News

Tabula Rasa HealthCare trades on the NASDAQ under the ticker symbol "TRHC."

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.07) by $0.01. The business had revenue of $74.27 million for the quarter, compared to analysts' expectations of $75.37 million. Tabula Rasa HealthCare had a negative net margin of 13.46% and a positive return on equity of 0.50%. View Tabula Rasa HealthCare's Earnings History.

Tabula Rasa HealthCare is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Tabula Rasa HealthCare.

Tabula Rasa HealthCare issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$282-285 million, compared to the consensus revenue estimate of $$289.21 million.

7 brokers have issued twelve-month price objectives for Tabula Rasa HealthCare's stock. Their forecasts range from $50.00 to $88.00. On average, they anticipate Tabula Rasa HealthCare's share price to reach $68.62 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price. View Analyst Price Targets for Tabula Rasa HealthCare.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tabula Rasa HealthCare in the last year. There are currently 2 hold ratings, 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tabula Rasa HealthCare.

Media coverage about TRHC stock has been trending somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tabula Rasa HealthCare earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Tabula Rasa HealthCare.

Tabula Rasa HealthCare saw a increase in short interest in December. As of December 31st, there was short interest totalling 7,360,000 shares, an increase of 9.4% from the December 15th total of 6,730,000 shares. Based on an average daily trading volume, of 319,800 shares, the short-interest ratio is presently 23.0 days. Currently, 36.5% of the shares of the stock are sold short. View Tabula Rasa HealthCare's Current Options Chain.

Some companies that are related to Tabula Rasa HealthCare include TriNet Group (TNET), Envestnet (ENV), Farfetch (FTCH), WNS (WNS), Sothebys (BID), HMS (HMSY), ExlService (EXLS), EVO Payments (EVOP), Cardtronics (CATM), Wageworks (WAGE), GreenSky (GSKY), Stamps.com (STMP), CBIZ (CBZ), Viad (VVI) and Conduent (CNDT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tabula Rasa HealthCare investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Canopy Growth (CGC), Adobe (ADBE), Micron Technology (MU), Netflix (NFLX), salesforce.com (CRM), VMware (VMW), QUALCOMM (QCOM) and Paypal (PYPL).

(TRHC) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Wells Fargo Securities, UBS Investment Bank and Piper Jaffray served as the underwriters for the IPO and Baird and Stifel were co-managers.

Tabula Rasa HealthCare's stock is owned by many different of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (1.51%), Artemis Investment Management LLP (1.26%), Summit Creek Advisors LLC (1.02%), Mirador Capital Partners LP (0.24%), State of Alaska Department of Revenue (0.07%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own Tabula Rasa HealthCare stock include Andrea Carolan Speers, Brian W Adams, Bruce Luehrs, Calvin H Knowlton, Dennis Helling, Gordon Tunstall, Orsula V Knowlton and Samira Beckwith. View Institutional Ownership Trends for Tabula Rasa HealthCare.

TRHC stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System and State of Alaska Department of Revenue. Company insiders that have sold Tabula Rasa HealthCare company stock in the last year include Andrea Carolan Speers, Brian W Adams, Calvin H Knowlton, Dennis Helling, Gordon Tunstall and Orsula V Knowlton. View Insider Buying and Selling for Tabula Rasa HealthCare.

TRHC stock was purchased by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Artemis Investment Management LLP, Peregrine Capital Management LLC and Mirador Capital Partners LP. View Insider Buying and Selling for Tabula Rasa HealthCare.

Shares of TRHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TRHC stock can currently be purchased for approximately $54.88.

Tabula Rasa HealthCare has a market capitalization of $1.22 billion and generates $204.27 million in revenue each year. The company earns $-47,270,000.00 in net income (profit) each year or $0.34 on an earnings per share basis. Tabula Rasa HealthCare employs 952 workers across the globe.View Additional Information About Tabula Rasa HealthCare.

The official website for Tabula Rasa HealthCare is http://www.tabularasahealthcare.com/.

Tabula Rasa HealthCare's mailing address is 228 STRAWBRIDGE DRIVE SUITE 100, MOORESTOWN NJ, 08057. The company can be reached via phone at 866-648-2767 or via email at [email protected]